Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Marc Braunstein

Myeloma · NYU Grossman Long Island

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View

Dr. Pavlos Msaouel

GU Oncology · MD Anderson Cancer Center

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    USDr. Urvi Shah

    Dr. Urvi Shah

    Hematology & Oncology · Myeloma
    Memorial Sloan Kettering Cancer Center
    urvi

    Research

    Oncologists' Knowledge and Attitudes Towards Providing Dietary Guidance to Patients with Cancer

    2026

    Via American Journal of Lifestyle Medicine

    Research

    Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in Patients with Multiple Myeloma Enrolled in the CARTITUDE-4 Trial

    2026

    Via Journal of Patient-Reported Outcomes

    Research

    Body Composition Predicts Poor Outcomes and Reveals Immunometabolic Dysfunction via Single-Cell Profiling in Anti-BCMA CAR T-Treated Myeloma

    2026

    Via HemaSphere

    Research

    Diabetes Mellitus in Multiple Myeloma and Related Plasma Cell Disorders: A Review of Risk, Prognosis, and Outcomes

    2026

    Via Blood Cancer Journal

    Research

    The Link between Modifiable Risk Factors and Myeloid Disorders — From Plate to Pathogenesis

    2026

    Via Blood Cancer Discovery

    Research

    Dietary patterns among individuals with plasma cell disorders — opportunities for targeted interventions

    2026

    Via Blood Cancer Journal

    Research

    A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model

    2026

    Via Cancer Discovery

    Research

    Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

    2026

    Via Blood Cancer Journal

    Research

    IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for newly diagnosed multiple myeloma

    2026

    Via Blood Advances

    Research

    A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients

    2026

    Via Blood Cancer Journal

    Research

    Diagnosis Disclosure and Related Illness Experience in Patients With Multiple Myeloma and Precursor Plasma Cell Disorders

    2026

    Via Clinical Lymphoma, Myeloma & Leukemia

    Research

    Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies

    2026

    Via Clinical Lymphoma, Myeloma & Leukemia

    Research

    Genomic features do not account for differences in multiple myeloma risk by ancestry

    2026

    Via Blood Cancer Discovery

    Research

    Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool

    2026

    Via Clinical Cancer Research

    Research

    A pilot trial evaluating lenalidomide and oral azacitidine with radiotherapy for patients with newly diagnosed and relapsed plasmacytoma

    2026

    Via Haematologica